EGFR L858R and T790M coexistence before first line therapy in pulmonary adenocarcinoma - case report

被引：0

作者：

Sousa, V. ^{[1
]}

Alarcao, A. ^{[1
]}

Ladeirinha, A. F. ^{[1
]}

Reis Silva, M. ^{[1
]}

Balseiro, S. ^{[1
]}

Ferreira, T. ^{[1
]}

d'Aguiar, M. J. ^{[1
]}

Figueiredo, A. ^{[1
]}

Barata, F. ^{[1
]}

Carvalho, L. ^{[1
]}

机构：

[1] UC, IAP, Fac Med, Coimbra, Portugal

来源：

VIRCHOWS ARCHIV | 2018年 / 473卷

关键词：

D O I：

暂无

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

E-PS-21-02

引用

页码：S315 / S315

页数：1

共 50 条

[21] Identification of Novel Fourth-Generation Allosteric Inhibitors Targeting Inactive State of EGFR T790M/L858R/C797S and T790M/L858R Mutations: A Combined Machine Learning and Molecular Dynamics Approach
Bhanja, Kousik K.
Patra, Niladri
JOURNAL OF PHYSICAL CHEMISTRY B, 2025,
[22] Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping
Juchum, Michael
Guenther, Marcel
Doering, Eva
Sievers-Engler, Adrian
Laemmerhofer, Michael
Laufer, Stefan
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (11) : 4636 - 4656
[23] Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report
Wang, Xia
Peng, Weiwei
Zeng, Zhimin
Cai, Jing
Liu, Anwen
FRONTIERS IN ONCOLOGY, 2021, 11
[24] Targeting wildtype and L858R/T790M mutant EGFR by isoliquiritigenin induces apoptosis and Inhibits tumor growth of NSCLC
Lee, Mee-Hyun
Jung, Sung Keun
Lim, Do Young
Cho, Yong-Yeon
Lee, Cheol-Jung
Song, Ji-Hong
Kim, Myoung Ok
Kim, Sung-Hyun
Bode, Ann M.
Dong, Zigang
CANCER RESEARCH, 2015, 75
[25] Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports
Li, Guangrui
Fang, Mei
Zhou, Yazhu
Liu, Xiaocui
Tian, Panpan
Mei, Fengjun
HELIYON, 2023, 9 (10)
[26] Synchronous driver gene alterations (EGFR L858R, T790M, and ROS1) rearrangements in a patient with early-stage lung adenocarcinoma
Masago, Katsuhiro
Kuroda, Hiroaki
Takahashi, Yusuke
Oya, Yuko
Sasaki, Eiichi
Sakakura, Noriaki
Matsushita, Hirokazu
CANCER GENETICS, 2022, 268-269 : 124 - 127
[27] The Alteration of T790M Prevalence Between 19 Deletions and L858R in NSCLC After EGFR-TKIs Therapy, a Meta-Analysis
Liang, H.
Chen, D.
He, J.
Liang, W.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1850 - S1851
[28] Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, cis-G796s/cis-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report
Chang, Yuan
Liu, Shuang
Jiang, Yanwen
Hua, Li
Wen, Linfang
RESPIRATORY MEDICINE CASE REPORTS, 2022, 36
[29] Discovery of highly potent and selective EGFR(T790M/L858R) TKIs against NSCLC based on molecular dynamic simulation
Yang, Tingting
Zhang, Wenjuan
Cao, Shengjie
Sun, Shiyang
Cai, Xu
Xu, Lei
Li, Pengyun
Zheng, Zhibing
Li, Song
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 228
[30] Noncovalent EGFR T790M/L858R inhibitors based on diphenylpyrimidine scaffold: Design, synthesis, and bioactivity evaluation for the treatment of NSCLC
Chen, Lixue
Zhang, Yunhao
Tian, Liangliang
Wang, Changyuan
Deng, Tuo
Zheng, Xu
Wang, Tong
Li, Zhen
Tang, Zeyao
Meng, Qiang
Sun, Huijun
Li, Lei
Ma, Xiaodong
Xu, Youjun
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 223

← 1 2 3 4 5 →